Amicus Therapeutics, Inc. (0HF9.L) LSE
17.09
+2.63(+18.19%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Amicus Therapeutics, Inc.
Address
3675 Market Street
Philadelphia, PA 19104
United States of America (the)
Phone
215 921 7600
Website
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
499
First IPO Date
January 29, 2018
Key Executives
| Name | Title | Pay | Year Born |
| Bradley L. Campbell | Chief Executive Officer, President & Director | 1.73M | 1976 |
| David Clark | Chief People Officer | 917,420 | 1976 |
| Simon Nicolas Reade Harford | Chief Financial Officer | 935,201 | 1960 |
| Jeffrey Castelli | Chief Development Officer | 960,912 | 1972 |
| Ellen S. Rosenberg | Chief Legal Officer & Corporate Secretary | 985,620 | 1964 |
| Jill Weimer | Chief Science Officer | 0 | N/A |
| Andrew Faughnan | Vice President of Investor Relations | 0 | N/A |
| Brendan McEvoy | Executive Director of External Communications | 0 | N/A |
| Patrik S. Florencio | Global Chief Compliance & Risk Officer | 0 | N/A |
| Samantha Prout | Chief Accounting Officer & Controller | 0 | 1979 |
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
